FDA OKs Clinical Trial to Test Bacteriophage-Based Treatment for Crohn’s

FDA OKs Clinical Trial to Test Bacteriophage-Based Treatment for Crohn’s
The U.S. Food and Drug Administration (FDA) recently cleared a Phase 1/2a clinical trial to study a set of bacteriophages designed to treat inflammatory bowel diseases (IBDs), specifically Crohn’s disease. The bacteriophages were developed as part of a July 2015 collaboration agreement between Intralytix and Ferring Pharmaceuticals. Together with French researchers from the University of Lille and Auvergne, the companies focused on studying a specific
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *